ImmunAbs

ImmunAbs has several antibody therapies in the global standard development for autoimmune diseases, diabetic retinopathy, and metabolic syndrome. ImmunAbs is developing IM-101, a targeted monoclonal antibody complement that plays a crucial role in the immune system but can cause various autoimmune diseases when uncontrolled, including but not limited to paroxysmal nocturnal hemoglobinuria (PNH). The complement inhibitor drug market achieved an annual growth rate of 20.7% in 2020, with a market size of $5.1 billion, and is expected to grow to $19 billion by 2027, demonstrating significant growth potential.